



Investor Presentation

Summer 2014

Edward Wright, CEO



Forward Looking Statements

The information in this presentation contains so-called "forward-looking" statements. These include statements regarding CRH Medical's expectations and plans relating to its business, statements about CRH Medical's expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "CRH Medical believes", "management believes", and similar language. All forward-looking statements are based on CRH Medical's current expectations and are subject to risks and uncertainties and to assumptions made. Assumptions include: (i) that the growth of CRH's product sales will continue in a consistent manner; (ii) CRH's costs will not escalate significantly; and (iii) CRH does not incur any extraordinary costs.

Important risk factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) we may not continue to attract Gastroenterologists and other licensed providers to purchase and use the CRH O'Regan System; (ii) the policies of health insurance carriers in the United States may affect the amount of revenue the Company receives; (iii) changes in United States federal or state laws, rules, and regulations; (iv) our senior management has been key to our growth, and we may be adversely affected if we lose any member of our senior management; (v) Our Clinical Sales Representatives may not be able to increase adoption of the CRH O'Regan System; (vi) economic dependence on suppliers and our contract manufacturer; (vii) changes in the industry and the economy may affect the Company's business; (viii) evolving regulation of corporate governance and public disclosure may result in additional corporate expenses; (ix) we may be subject to competition and technological risk which may impact the price and amount of product we can sell; * we may be subject to product liability which may adversely affect our operations; (xi) we may need to raise additional capital to fund future operations; (xii) our business may be impacted by health care reform in the United States; (xiii) we may not have the expertise required to expand internationally. As a single product company, any adverse event directly or indirectly related to the CRH O'Regan System will have a material impact on the Company's financial performance. CRH Medical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them, except as required by law.



Colorectal Cancer is 95% preventable with screening. Unless you cover it up and pretend it isn't there.

 The Colorectal Cancer Screening Alliance

www.colorectal.org

It's a great time to be a
GASTROENTEROLOGIST

15M

colonoscopies performed
ANNUALLY IN THE U.S.



by **8,500**
gastroenterologists



up
to **20%**

of colonoscopy patients
HAVE HEMORRHOIDS



Often, GI's do
NOTHING
for them



Market Opportunity

15M colonoscopies per year

20% hemorrhoids

3M available patients

2.5 average treatments per patient


7.5M available treatments

\$65 revenue to CRH per treatment

CRH's market opportunity

\$500M

Significant upside



Approximately
6,800 gastroenterologists
have not been trained yet

Approximately
1,700 gastroenterologists
trained to date

A **small percentage**
of our customers account for
most of our revenue

More GIs, More Power users


**A MARKETING &
DISTRIBUTION**
company focused on
GI practices

Creates awareness for
their practices

Provides patients with a safe
and effective product

Help GIs increase procedures

Our Value Proposition



>490,000
procedures performed

The CRH O'Regan System

- Intellectual property
- Manufacturing
- Marketing
- Distribution to physicians



The O'Regan System is Clinically Proven

Iain M. Cleator, Mihaela M. Cleator
The Long Term Results of Hemorrhoid Banding Using The CRH O'Regan Disposable Suction Ligator

Christina Frangou. **Which Hemorrhoid Therapy? Expert Reviews**
Options Gastroenterology and Endoscopy News, May 2009 & *General Surgery News*, April 2009

Neal Osborn, MD, MSc. **Hemorrhoid Treatment Using Rubber Band Ligation**, *The Journal of Medicine*, November/December 2009

Cheetham MJ, Cohen CR, Kamm MA et al. **A randomized, controlled trial of diathermy hemorrhoidectomy vs. stapled hemorrhoidectomy in an intended day-care setting with long-term follow-up.** *Dis Colon Rectum*. 2003 Apr;46(4):491-7.

Mitchel Guttenplan, MD, FACS, David A. Johnson, MD, FACP, FAGC, FASGE, Bergein Overholt, MD, MACG, FACP, FASGE **Hemorrhoid Care Rubber Band Ligation Using the CRH O'Regan System™** EndoEconomics, Winter 2010

Aliberti LC. **The flexible sigmoidoscope as a potential vector of infectious disease, including suggestions for decontamination of the flexible sigmoidoscope.** *Yale J Biol Med*. 1987 Jan-Feb;60(1):19-26.

Iain M. Cleator, Mihaela M. Cleator, David Johnson, Bergein F. Overholt **Eight Years of Hemorrhoid Banding Experience with the O'Regan Ligator**

Neal Osborn, MD, MSc **Hemorrhoid Treatment: The Gastroenterologist Perspective. A Year in Review.**

Cheetham MJ, Mortensen NJ, Nyström PO et al. **Persistent pain and fecal urgency after stapled hemorrhoidectomy.** *Lancet*. 2000 Aug 26;356:730-3.

Sutherland LM, Burchard AK, Matsuda K et al **A systematic review of stapled hemorrhoidectomy.** *Arch Surg*. 2002 Dec;137(12):1395-406; discussion 1407.

(HIS) programme: analysis of a two-year pilot. *J Hosp Infect*. 2003 Apr;53(4):259-67.

Neal Osborn, MD, MSc, Jeffrey Higgins-Walzer, Steven Mc **Hemorrhoid Treatment in Outpatient Gastroenterology Practice Using the O'Reg Disposable Bander is Safe and Effective**

Gordon V. Onning, MD, PhD, Gustavo A. Machicado, MD, Dennis M. Jensen, MD **Definitive Therapy for Internal Hemorrhoids—New Opportunities and Options 2009**

Dimitrios Paikos, et al. **"Banding Hemorrhoids Using the O'Regan Disposable Bander. Single Center Experience."**

Harry E. Sarles, Jr., MD, FAGC **Increase Your EASC and Practice Bottom Line by Providing Hemorrhoidal Treatment** Fall 2008

Robert A. Ganz, MD, FASGE **Healthcare "Reform" — A Potential Crisis For Practitioners!**

Jack... **Comprehensive Non-Surgical Anorectal Care to the Gastroenterology Fellowship Training: The University of South Alabama Experience**

> **99%** effective in peer-reviewed studies

Physician Relations

- Meaningful relationships with KOLs
- Constant interaction with physicians and their practices
- Publications/scientific papers
- Strong presence at medical conferences
- Participation in fellowship programs





MAINTAINING SUSTAINABLE RELATIONSHIPS

> 75%

of practices trained become
active users of the O'Regan System

Referral Marketing

You Have Hemorrhoids. Now What?

You have been diagnosed with hemorrhoids. We know you may be in discomfort and are perhaps worried, but now that you know what the problem is, you can do something about it!

Hemorrhoids are best treated before they become so severe that they require surgery, which can be expensive, painful and require a prolonged recovery. The following recommendations are helpful for minimizing an initial bout of rectal bleeding, itching and pain.

While you wait to be treated with the CRH O'Regan System®, here are some helpful tips to reduce the discomfort from your hemorrhoids:

1. Take a 15-minute sitz bath (a warm bath with a tablespoon of table salt added) three times per day and after each bowel movement if possible. Gently dry your bottom.
2. Avoid constipation by increasing the amount of fiber and liquids in your diet. Stool softeners may also be helpful to avoid constipation.
3. Avoid sitting on the commode for more than two minutes to prevent excessive straining. If you can't have a bowel movement in that time, come back later.
4. Avoid prolonged sitting or other activities that will increase the pressure on your bottom. If you work at a desk all day, get up and take breaks whenever you can.
5. There are many creams or suppositories for hemorrhoids, but they have limited benefits.

The Experts Speak



CRH O'Regan System®
Non-Surgical Hemorrhoid Treatment
Fast. Painless. Proven.



The CRH O'Regan System® is a product of CRH Medical Corporation

www.crhsystem.com

Say goodbye to hemorrhoids




"The procedure was not only painless but it put an instant end to my discomfort. I'm just sorry I didn't do it sooner."

CRH O'Regan System®
Non-Surgical Hemorrhoid Treatment
Fast. Painless. Proven.

www.crhsystem.com

Online Lead Development



Consumer Awareness



Got Hemorrhoids?

Don't keep treating them.
Remove them!

Treating your symptoms with messy creams and ointments only provides temporary relief. So don't keep treating hemorrhoids, remove them. It's time you feel your best again.



The CRH O'Regan System® utilizes a non-surgical, patented device.

- ✔ Quick, effective & painless
- ✔ No prep, no sedation
- ✔ Return to work the same day

CRH O'Regan System®

Non-Surgical Hemorrhoid Removal
Fast. Painless. Proven.

SAMPLE AD TEMPLATE
Your practice information here.
Contact us to customize this template:
practicesupport@crhmedcorp.com or 1.800.660.2153

The CRH O'Regan System® may not be appropriate for all patients. You and your physician will determine an appropriate treatment for your diagnosis during your examination.

The CRH O'Regan System® is a product of CRH Medical Corporation.


TV

Print

Radio

Top-line Growth

Steady increase in revenue for CRH



Consistently Profitable, Growing Cash

13

**CONSECUTIVE
PROFITABLE QUARTERS**

Q1 2014 net income of
\$368 K

7.4M

**CASH AT THE END
OF Q1, 2014**

12% more than at Q4,
2013

Revenue Opportunity For GIs

+16%

more revenue per minute for
ligation versus colonoscopy

GIs receive comparable
reimbursement to
endoscopic procedures

\$264.81 Ligation 46221
(12 minute procedure in office)
(\$376.38 in EASC)

\$570.42 Colonoscopy 45378
(30 minute procedure in EASC)

Achieving **OPERATIONAL SCALE**

Goodwill created with the **GI community** uniquely positions us to evaluate...

- **Innovative new products or services**
- **Opportunities to leverage our platform**

Market Size

1 in 2

will have hemorrhoids by age 50

CRH will capitalize on that market with:

A great product that generates revenue for clinical practices

Its continuum of care for the patient

Backed up by industry leading marketing

Management and Directors

EDWARD WRIGHT CEO/Director
Former Executive Vice President of Retail in
North America for Cartier

RICHARD BEAR CFO
Former CFO ID Biomedical

DR. MITCHELL GUTTENPLAN
Medical Director
Board Certified General Surgeon

DR. ANTHONY F. HOLLER
Chairman of the Board
Former CEO of ID Biomedical

DR. IAIN CLEATOR
Director and Medical Director
Professor Emeritus of Surgery at the University
British Columbia

DR. DAVID A. JOHNSON, FACP, FACG,
FASGE. Director
Past President of American College of
Gastroenterology

DR. BERGEIN F. OVERHOLT, FACP, MACG
Director
Past President of the American Society for
Gastrointestinal Endoscopy

TODD PATRICK Director
Former President and Chief Operating Officer
of ID Biomedical Corporation

IAN WEBB Director
Retired partner of the law firm, Borden
LadnerGervais LLP

Cap Structure

Shares outstanding	48.8M
Fully-diluted	56.1M
Symbols	TSX:CRH OTCQX: CRMMF
Market cap*	\$40M
Average daily volume**	47,351
Cash (03/31/2014)	\$7.4M
Management & insiders fully diluted	9%
Institutional ownership	18%

*as at April 25, 2014

** April 25, 2013- April 25, 2014



Investor Presentation

Summer 2014

Edward Wright, CEO

